Aiding the EU and US with avian influenza preparedness CSL Seqirus was selected by the Health Emergency Preparedness and Response Authority (HERA), part of the European Commission (EC), to deliver 665,000 pre‑pandemic vaccine doses for 15 EU and EEA Member States as well as to the “Union Civil Protection Mechanism” (rescEU). The vaccine is well-matched to the H5 of the H5N1 strain circulating in 2024. This acquisition of pre-pandemic (zoonotic) vaccine will create a stockpile of vaccines available to support the EC’s outbreak and pre‑pandemic response. In addition, the four-year contract includes an option for participating authorities to purchase up to an additional 40 million doses of the pre-pandemic vaccine over the life of the contract. The vaccines are being manufactured in CSL Seqirus’ European manufacturing sites in which utilises a scalable method of production. CSL Seqirus was also selected by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to complete the fill and finish process of pre-pandemic vaccine for the U.S. government as part of the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) program. Under the terms of the agreement, CSL Seqirus will deliver approximately 4.8 million doses of pre-pandemic vaccine that is well-matched to the H5 of the currently circulating H5N1 strain. The vaccines will be produced at CSL Seqirus’ manufacturing facility in Holly Springs (US), which is the largest cell-based influenza vaccine producer in the world and is the first such facility in the US. Healthier World Supporting World Health Organization’s pandemic influenza preparedness Over the reporting period, CSL Seqirus continued its multi-million‑dollar financial support for the World Health Organization’s (WHO) Pandemic Influenza Preparedness (PIP) Framework. The PIP Framework brings together Member States, industry, other stakeholders and WHO to implement a global approach to pandemic influenza preparedness and response. Its key goals include: to improve and strengthen the sharing of influenza viruses with human pandemic potential; and to increase the access of developing countries to vaccines and other pandemic related supplies. 46 Limited Annual Report 2023/24
RkJQdWJsaXNoZXIy MjE2NDg3